/ Scientists

Marcia Belvin

Associate Director, Translational Oncology

"Working at Genentech, you are surrounded by people who are driven by the same goal - improving patients' lives. It's a company-wide vision that motivates everyone. I feel very fortunate to have such an important goal to strive for and to work in a company with the means to achieve it."

9
years at Genentech
29
publications (2010-12)

I started at Genentech in the fall of 2004 after having been in the biotech industry for six years. The benefits of being at Genentech were immediately clear - working in a research-driven company with extremely smart, collaborative colleagues who all share a passion for translating science into help for cancer patients.

Featured Publication

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Nature 2010 Feb 3
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S
View Abstract on PubMed

My Focus

Our group focuses on understanding several of the major signaling pathways that drive solid tumor growth, and using this knowledge to help determine which pathway components are the best to target, and which patients will benefit the most from inhibiting those targets. We work with compounds at various stages of development to understand the effects of those compounds in cancer cells, both as single agents and when used in combination with other drugs.
Publications
- Systems-wide analysis of K-Ras, Cdc42 and PAK4 signaling by quantitative phosphoproteomics
  Molecular and Cellular Proteomics, 2013, ISSN: 1535-9476
  Gnad, Florian; Young, Amy; Zhou, Wei; Lyle, Karen; Ong, Christy C; Stokes, Matthew P; Silva, Jeffrey C; Belvin, Marcia; Friedman, Lori S; Koeppen, Hartmut; Minden, Audrey; Hoeflich, Klaus
  View on PubMed
- Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform
  Bioorganic & Medicinal Chemistry Letters, 2013, ISSN: 0960-894X
  Staben, Steven T; Ndubaku, Chudi; Blaquiere, Nicole; Belvin, Marcia; Bull, Richard J; Dudley, Danette; Edgar, Kyle; Gray, Daniel; Heald, Robert; Heffron, Timothy P; Jones, Graham E; Jones, Mark; Kolesnikov, Aleks; Lee, Leslie; Lesnick, John; Lewis, Cristina; Murray, Jeremy; McLean, Neville J; Nonomiya, Jim; Olivero, Alan G; Ord, Rachel; Pang, Jodie; Price, Stephen; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Wallin, Jeff; Wang, Lan; Wei, Binqing; Weismann, Christian; Wu, Ping
  View on PubMed
- Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models
  Clinical Cancer Research, 2013, ISSN: 1078-0432
  Lin, Jie; Sampath, Deepak; Nannini, Michelle A; Lee, Brian B; Degtyarev, Michael; Oeh, Jason; Savage, Heidi; Guan, Zhengyu; Hong, Rebecca; Kassees, Robert; Lee, Leslie B; Risom, Tyler; Gross, Stefan D; Liederer, Bianca; Koeppen, Hartmut; Skelton, Nicholas; Wallin, Jeffrey J; Belvin, Marcia; Punnoose, Elizabeth A; Friedman, Lori S; Lin, Kui
  View on PubMed
- Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
  ACS Medicinal Chemistry Letters, 2012, ISSN:
  Pei, Zhonghua; Blackwood, Elizabeth; Liu, Lichuan; Malek, Shiva; Belvin, Marcia; Koehler, Michael F. T.; Ortwine, Daniel F.; Chen, Huifen; Cohen, Frederick; Kenny, Jane R.; Bergeron, Philippe; Lau, Kevin; Ly, Cuong; Zhao, Xianrui; Estrada, Anthony A.; Truong, Tom; Epler, Jennifer A.; Nonomiya, Jim; Trinh, Lan; Sideris, Steve; Lesnick, John; Bao, Linda; Vijapurkar, Ulka; Mukadam, Sophie; Tay, Suzanne; Deshmukh, Gauri; Chen, Yung-Hsiang; Ding, Xiao; Friedman, Lori S.; Lyssikatos, Joseph P.
  View on PubMed
- An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer
  Cancer Research, 2012, ISSN: 0008-5472
  McCleland, Mark L; Adler, Adam S; Shang, Yonglei; Hunsaker, Thomas; Truong, Tom; Peterson, David; Torres, Eric; Li, Li; Haley, Benjamin; Stephan, Jean-Philippe; Belvin, Marcia; Hatzivassiliou, Georgia; Blackwood, Elizabeth M; Corson, Laura; Evangelista, Marie; Zha, Jiping; Firestein, Ron
  View on PubMed
- PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
  Cancer Chemotherapy and Pharmacology, 2012, ISSN: 0344-5704
  Choo, Edna F; Ng, Chee M; Berry, Leanne; Belvin, Marcia; Lewin-Koh, Nicholas; Merchant, Mark; Salphati, Laurent
  View on PubMed
- mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations
  Cancer Letters, 2012, ISSN: 0304-3835
  Vijapurkar, Ulka; Robillard, Liliane; Zhou, Siqun; Degtyarev, Michael; Lin, Kui; Truong, Tom; Tremayne, Jarrod; Ross, Leanne Berry; Pei, Zhonghua; Friedman, Lori S; Blackwood, Elizabeth M; Belvin, Marcia
  View on PubMed
- Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions
  Journal of Medicinal Chemistry, 2012, ISSN: 0022-2623
  Heald, Robert A.; Jackson, Philip; Savy, Pascal; Jones, Mark; Gancia, Emanuela; Burton, Brenda; Newman, Richard; Boggs, Jason; Chan, Emily; Chan, Jocelyn; Choo, Edna; Merchant, Mark; Rudewicz, Patrick; Ultsch, Mark; Wiesmann, Christian; Yue, Qin; Belvin, Marcia; Price, Steve
  View on PubMed
- GDC-0941, A Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
  Clinical Cancer Research, 2012, ISSN: 1078-0432
  Wallin, Jeffrey J; Guan, Jane; Prior, Wei Wei; Lee, Leslie B; Berry, Leanne; Belmont, Lisa D; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S; Sampath, Deepak;
  View on PubMed
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
  Molecular Cancer Therapeutics, 2012, ISSN: 1535-7163
  Hatzivassiliou, Georgia; Liu, Bonnie; O'Brien, Carol; Spoerke, Jill M; Hoeflich, Klaus P; Haverty, Peter M; Soriano, Robert; Forrest, William F; Heldens, Sherry; Chen, Huifen; Toy, Karen; Ha, Connie; Zhou, Wei; Song, Kyung; Friedman, Lori S; Amler, Lukas C; Hampton, Garret M; Moffat, John; Belvin, Marcia; Lackner, Mark R;
  View on PubMed
- Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes
  PLoS ONE, 2012, ISSN: 1932-6203
  Wallin, Jeffrey J; Guan, Jane; Edgar, Kyle A; Zhou, Wei; Francis, Ross; Torres, Anthony C; Haverty, Peter M; Eastham-Anderson, Jeffrey; Arena, Sabrina; Bardelli, Alberto; Griffin, Sue; Goodall, John E; Grimshaw, Kyla M; Hoeflich, Klaus P; Torrance, Christopher; Belvin, Marcia; Friedman, Lori S
  View on PubMed
- Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions
  Drug Metabolism and Pharmacokinetics, 2012, ISSN: 0090-9556
  Choo, Edna F; Belvin, Marcia; Boggs, Jason; Deng, Yuzhong; Hoeflich, Klaus P; Ly, Justin; Merchant, Mark; Orr, Christine; Plise, Emile; Robarge, Kirk; Martini, Jean F; Kassees, Robert; Aoyama, Ron G; Ramaiya, Atulkumar; Johnston, Stuart H;
  View on PubMed
- GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
  Molecular Cancer Therapeutics, 13 Oct 2011, ISSN: 1538-8514.
  Wallin, Jeffrey J; Edgar, Kyle A; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G; Sutherlin, Daniel P; O, Brien Carol; Spoerke, Jill M; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S
  View on PubMed
- p21-activated kinase 1: PAK'ed with potential.
  Oncotarget, {Oncotarget}, 7 Jun 2011 (epub: 7 6 2011), ISSN: 1949-2553.
  Ong, Christy C; Jubb, Adrian M; Zhou, Wei; Haverty, Peter M; Harris, Adrian L; Belvin, Marcia; Friedman, Lori S; Koeppen, Hartmut; Hoeflich, Klaus P
- Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer.
  Science Translational Medicine, 2010, ISSN:
  Wallin, J.J.; Guan, J.; Prior, W.W.; Edgar, K.A.; Kassees, R.; Sampath, D.; Belvin, M.; Friedman, L.S.
- PK-PD Modeling of Combination Efficacy Effect from Administration of a MEK Inhibitor, GDC-0973 and PI3K Inhibitor, GDC-0941 in A2058 Xenografts.
  Drug Metabolism Reviews, 2010, ISSN: 0360-2532
  Choo, E.F.; Belvin, M.; Hoeflich, K.; Merchant, M.; Otter, D.D.; Salphati, L.
- Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor.
  Xenobiotica, 2010, ISSN: 0049-8254
  Choo, E.; Belvin, M.; Chan, J.; Hoeflich, K.; Orr, C.; Robarge, K.; Yang, X.; Zak, M.; Boggs, J.
- Mutant PIK3CA increases the expression of individual tubulin isoforms and promotes resistance to anti-mitotic chemotherapy drugs.
  Proceedings of the American Association for Cancer Research Annual Meeting, 2010, ISSN: 0197-016X
  Wallin, J.; Guan, J.; Xiao, Y.; O'Brien, T.; Belvin, M.; Friedman, L.
- P21-activated kinase-1 (PAK1) as a therapeutic target in cancer.
  Proceedings of the American Association for Cancer Research Annual Meeting, 2010, ISSN: 0197-016X
  Ong, C.; Jubb, A.; Truong, T.; Zhou, W.; Tran, V.; Haverty, P.; Turley, H.; Vucic, D.; Belvin, M.; Blackwood, E.; Harris, A.; Friedman, L.; Koeppen, H.; Hoeflich, K.
- PI3K inhibitor GDC-0941 synergizes with mTOR inhibitors by blocking negative feedback and causes distinct effects on signaling and apoptosis compared to a dual PI3K/mTOR inhibitor.
  Proceedings of the American Association for Cancer Research Annual Meeting, 2010, ISSN: 0197-016X
  Vijapurkar, U.; Robillard, L.; Friedman, L.; Belvin, M.
- Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer.
  Science Translational Medicine, 2010, ISSN: 1946-6242
  Wallin, J.; Guan, J.; Prior, W.-W.; Edgar, K.; Kassees, R.; Sampath, D.; Belvin, M.; Friedman, L.
- Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941.
  Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010, ISSN: 1521-009X
  Salphati, L.; Wong, H.; Belvin, M.; Bradford, D.; Edgar, K.; Prior, W.; Sampath, D.; Wallin, J.
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models.
  Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2010, ISSN: 1078-0432
  O'Brien, C.; Wallin, J.; Sampath, D.; Guhathakurta, D.; Savage, H.; Punnoose, E.; Guan, J.; Berry, L.; Prior, W.-W.; Amler, L.; Belvin, M.; Friedman, L.; Lackner, M.
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
  Nature, 2010, ISSN: 1476-4687
  Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K.P.; Jaiswal, B.S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L.S.; Malek, S.
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors.
  Cancer Research, 2010, ISSN: 1538-7445
  Edgar, K.A.; Wallin, J.J.; Berry, M.; Lee, L.B.; Prior, W.W.; Sampath, D.; Friedman, L.S.; Belvin, M.
- In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
  Clinical Cancer Research, 2009, ISSN: 1078-0432
  Hoeflich, K.P.; O'Brien, C.; Boyd, Z.; Cavet, G.; Guerrero, S.; Jung, K.; Januario, T.; Savage, H.; Punnoose, E.; Truong, T.; Zhou, W.; Berry, L.; Murray, L.; Amler, L,; Belvin, M.; Friedman, L.S.; Lackner, M.R.
- Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
  Clinical Cancer Research, 2009, ISSN: 1078-0432
  Yao, E.; Zhou, W.; Lee-Hoeflich, S.T.;Truong T.; Haverty, P.M.;Eastham-Anderson, J.; Lewin-Koh, N.; Gunter, B.; Belvin, M.; Murray, L.J.; Friedman, L.S.; Sliwkowski, M.X.; Hoeflich, K.P.
- Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF^V600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
  Cancer Research, 2009, ISSN: 1538-7445
  Hoeflich, K.P.; Herter, S.; Tien, J.; Wong, L.; Berry, L.; Chan, J.; O'Brien, C.; Modrusan, Z.; Seshagiri, S.; Lackner, M.; Stern, H.; Choo, E.; Murray, L.; Friedman, L.S.; Belvin, M.
- Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 in
  Journal of Pharmacology & Experimental Therapeutics, 2009, ISSN: 1521-0103
  Wong, H.; Belvin, M.; Herter, S.; Hoeflich, K.P.; Murray, L.J.; Wong, L.; Choo, E.F.
Education
- Cold Spring Harbor, Postdoctoral Fellow – 1998
- University of California Berkeley, Ph.D – 1995
- Harvard University, B.A. – 1988

Marcia Belvin

Associate Director, Translational Oncology

Featured Publication

Systems-wide analysis of K-Ras, Cdc42 and PAK4 signaling by quantitative phosphoproteomics

Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform

Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models

Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349

An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations

Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions

GDC-0941, A Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes

Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.

p21-activated kinase 1: PAK'ed with potential.

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer.

PK-PD Modeling of Combination Efficacy Effect from Administration of a MEK Inhibitor, GDC-0973 and PI3K Inhibitor, GDC-0941 in A2058 Xenografts.

Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor.

Mutant PIK3CA increases the expression of individual tubulin isoforms and promotes resistance to anti-mitotic chemotherapy drugs.

P21-activated kinase-1 (PAK1) as a therapeutic target in cancer.

PI3K inhibitor GDC-0941 synergizes with mTOR inhibitors by blocking negative feedback and causes distinct effects on signaling and apoptosis compared to a dual PI3K/mTOR inhibitor.

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer.

Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941.

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors.

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 in

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF^V600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.